Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation

This article was originally published in The Tan Sheet

Executive Summary

Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.

You may also be interested in...



Complaint Reminds CVS: No Support For Memory Claim In Fish Oil Study

A complaint filed by CSPI working with law firms in New York and Washington extends the dispute over cognitive claims for vitamin and supplement products from enforcement by FTC and FDA and questions from Congress to consumers' class action complaints.

Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN

Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.

Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN

Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel